Flu cases are on the rise in Pennsylvania and New Jersey

The CDC reports an uptick in 2025-26 seasonal influenza with estimated 4.6 million illnesses, 49,000 hospitalizations and 1,900 deaths so far, while historical seasons have ranged from 96,000 to 700,000 hospitalizations and 6,300 to 51,000 deaths. State-level data show Pennsylvania with 11,432 lab-confirmed flu cases (plus 2,300 RSV cases and rising COVID-19 wastewater signals) and New Jersey with 6,904 flu cases, 2,179 RSV and 1,702 COVID cases as of Dec. 13; about 130 million flu vaccine doses have been distributed. The rise in respiratory illnesses bears monitoring for potential near-term impacts on workforce availability, healthcare utilization and consumer activity over the holidays.

Analysis

Market structure: Rising flu + co-circulating COVID/RSV is a positive demand shock for diagnostics (rapid antigen/PCR), retail immunization channels, antivirals and inpatient care while creating short-term headwinds for travel/leisure and discretionary spend if hospitalizations spike. With ~130m flu vaccine doses distributed and confirmed season cases already in the millions, expect a 10–30% sequential lift in test volumes and pharmacy foot traffic through Jan–Feb versus Oct–Nov, giving diagnostic makers and pharmacies modest pricing/volume leverage.

Risk assessment: Immediate risk (days–weeks) is holiday travel-driven transmission; short-term (weeks–months) risk is hospital strain and staffing shortages; tail risks include a vaccine-mismatch season raising hospitalizations >150k (historical lower bound ~96k) or antiviral/test supply disruptions forcing government procurement and price negotiation. Hidden dependencies: wastewater/COVID trends and school/workplace closures amplify effects; key catalysts are CDC weekly hospitalization updates, state-level hospitalization thresholds and antiviral stock alerts.

Trade implications: Favor equity exposure to diagnostics and retail immunizers and underweight travel/leisure: tactically overweight ABT and QDEL (see sizing below), add CVS/WBA for incremental in-store revenue; consider 2–3 month call spreads to capture Jan peak and delta protectives for hospital operators. Use a relative-value pair (long ABT, short AAL) to capture asymmetric upside in testing demand vs. travel sensitivity; hedge macro tail with 3–6 month T-bills or 2s/10s flatteners if risk-off emerges.

Contrarian angle: The market underprices operational leverage in mid-cap diagnostics and overreacts to headline case counts for travel names; history (seasonal flu spikes) shows durable, but time-limited, revenue bumps for tests/retail immunizers and transitory margin pressure for hospitals. Watch for policy responses (state bulk purchases or price caps) which could compress diagnostic ASPs and flip trades quickly.

Key Decisions for Investors

• Establish a 2–3% long position in Abbott Laboratories (ABT) and a 1–2% long position in QuidelOrtho (QDEL) to capture a projected 10–30% increase in test volumes into Jan–Feb; scale in now and add up to 50% more if CDC national hospitalization weekly growth >10% week-over-week.
• Take a 2% tactical long in CVS Health (CVS) or Walgreens Boots Alliance (WBA) to capture extra walk-in vaccination revenue and OTC sales through Q1 2026; trim if pharmacy comps fail to beat consensus by >200bps in Jan earnings.
• Implement a pair trade: long ABT (2%) / short American Airlines (AAL) (1.5%) to isolate testing/vaccination upside versus travel sensitivity; unwind short AAL if TSA throughput recovers +10% m/m or if CDC declares no elevated travel risk.
• Buy 3-month ABT and QDEL call spreads (near-the-money strikes) sized to limit capital at risk to 0.5% of portfolio each to monetize peak-season volatility; simultaneously buy 1–2% portfolio allocation in 3–6 month T-bills as a downside hedge against a severe tail event.
• Reduce cyclical leisure/hospitality exposure (Marriott MAR, Hilton HLT) by 1–3% if state hospitalization rates exceed their historical seasonal medians (e.g., >150 hospitalizations/day per 100k population in a state) or if combined flu+COVID wastewater signal rises >20% in two consecutive weeks.